December 5, 2022 Quanterix’s Simoa® Technology Drives Advances in Alzheimer’s Disease Research Presented at 2022 Clinical Trials on Alzheimer’s Disease (CTAD) Conference read more
August 8, 2022 Quanterix Corporation Releases Operating Results for Second Quarter 2022, Announces Business Re-Alignment Plan and Revises 2022 Guidance read more
July 27, 2022 Quanterix Launches First pTau-181 Plasma Laboratory Developed Test for Clinical Diagnostic and Research Applications in the U.S. read more
April 22, 2022 Quanterix Granted Breakthrough Device Designation from U.S. FDA for NfL Test for Multiple Sclerosis read more
April 4, 2022 Quanterix’ Simoa® Technology Powers Large, International Comprehensive Reference Range Study Utilizing Serum Neurofilament Light (sNfL) to Assess Disease Activity in Multiple Sclerosis (MS) Patients read more
March 29, 2022 Quanterix Receives Funding from the Alzheimer’s Drug Discovery Foundation to Accelerate Alzheimer’s Disease Diagnostic Plasma Test Development read more
February 28, 2022 Quanterix Corporation Garners Five Best Places to Work Awards from Comparably read more